Company intelligence / Profile preview

Cibiltech

Paris, France

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Cibiltech's CE-marked Predigraft software leverages AI to predict long-term kidney allograft survival based on robust clinical data; the company has initiated an international, randomized clinical trial and its solution is commercialized in the EU and via partnership in the US[2][3][4][5].

Therapeutic areas: NephrologyImmunology
Modalities: DeviceDigital biomarkerNon-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

CareDx (exclusive US commercial rights for Predigraft, minority equity holder)[5]

Beyond the preview

Go deeper on Cibiltech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cibiltech.

Explore the full profile